Remote Loading by AS Gradient

the first liposomal drug that was approved by the Food and Drug Administration, in 1995, is a good example of the successful application of a transmembrane inner liposome high/outer liposome low ammonium ion gradient for remote loading of an amphipathic weak base, the anticancer 

Main requirements to achieve therapeutically efficacious passive targeting of liposomes 

Physicochemical and biophysical solutions used to meet the requirements 

Extended circulation time in intact form in the plasma 

Sufficient stable loading of drug in order to reach disease site with liposomes loaded with drug at a level needed to achieve therapeutic efficacy Extravasation into diseased tissue (tumor or inflamed sites) 

---